Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07492043

Breast Tumour Size Measurement by Field Cycling Imaging

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is:

Can FCI accurately estimate DCIS lesion size compared with histology results?

Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Cancer Adenocarcinoma Breast Carcinoma In Situ Breast Diseases Breast Neoplasms Carcinoma Carcinoma in Situ Carcinoma, Intraductal, Noninfiltrating Ductal Carcinoma in Situ Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Glandular and Epithelial Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females ≥ 18 years old.
  • Subjects diagnosed with DCIS on initial biopsy.
  • Lesion size >1 cm on imaging.
  • Subjects undergoing surgery as part of their treatment.
  • Able to fit comfortably in the scanners.
  • Able to understand written and spoken English.

Exclusion criteria

  • Subjects undergoing chemotherapy or hormonal therapy.
  • Individuals unable to give informed consent.
  • Contra-indications to MRI scanning such as implantable cardiac devices.
  • Known allergy to contrast agent.

Treatment and study plan

Field-Cycling Imaging research scan

Other

Baseline FCI scan

3T MRI research scan

Other

Baseline MRI scan

Primary outcomes

  1. Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard).

    Time frame: Baseline

    Extent of agreement between lesion size estimation by FCI and actual lesion size according to NHS histopathology results.

Secondary outcomes

  1. Comparison of DCIS lesion measurements using FCI and 3T MRI.

    Time frame: Baseline

    Extent of agreement in lesion size measurements between FCI and conventional 3T MRI.

Study contacts

Contact information is provided by the study sponsor or research team.

Vasiliki Mallikourti, PhD

CONTACT

[email protected]

+44 1224 437831

Sponsors and collaborators

Lead sponsor

University of Aberdeen

Other

Collaborators

  • NHS Grampian

Registry information

Acronym: BREVIA

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 25, 2026
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.